(4-(4-(benzylamino)quinazolin-2-yl)piperazin-1-yl)(phenyl)methanone | 1095661-25-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: (4-(4-(benzylamino)quinazolin-2-yl)piperazin-1-yl)(phenyl)methanone
• 英文别名: [4-[4-(Benzylamino)quinazolin-2-yl]piperazin-1-yl]-phenylmethanone
• CAS: 1095661-25-8
• 化学式: C₂₆H₂₅N₅O
• 分子量: 423.517
• InChiKey: GEQIAKZNDXZWBF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  61.4
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS
  申请人：Wynne Graham Michael

  公开号：US20100317607A1

  公开（公告）日：2010-12-16

  Compounds of a compound of compound of general formula (I) wherein X 1 , X 2 , A, R 1 R 2 , R 3 and R 4 are as defined herein; are useful as anti-mycobacterial agents, especially agents for the treatment of tuberculosis.

  在本文中，化合物的一般公式（I）中，X1、X2、A、R1、R2、R3和R4的定义如上所述；这些化合物可用作抗分枝杆菌剂，特别是用于治疗结核病的药剂。
• CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE
  申请人：Sanofi-Aventis

  公开号：EP2170890A2

  公开（公告）日：2010-04-07
• [EN] USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS<br/>[FR] UTILISATION DE COMPOSÉS POUR LA PRÉPARATION D'AGENTS ANTI-TUBERCULOSE
  申请人：SUMMIT CORP PLC

  公开号：WO2009001060A2

  公开（公告）日：2008-12-31

  [EN] Compounds of a compound of compound of general formula (I) wherein X1, X2, A, R1 R2, R3 and R4 are as defined herein; are useful as anti-mycobacterial agents, especially agents for the treatment of tuberculosis.
  [FR] L'invention concerne des composés représentés par la formule générale (I) dans laquelle X1, X2, A, R1 R2, R3 et R4 sont tels que définis présentement. Ces composés sont utiles comme agents antimycobactériens, notamment comme agents pour le traitement de la tuberculose.
• [EN] CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE<br/>[FR] AGENTS CYTOTOXIQUES COMPRENANT DE NOUVEAUX DÉRIVÉS DE LA TOMAYMYCINE ET LEUR UTILISATION THÉRAPEUTIQUE
  申请人：SANOFI AVENTIS

  公开号：WO2009016516A2

  公开（公告）日：2009-02-05

  The invention relates to novel tomaymicine derivatives comprising a linker. It also relates to the conjugate molecules that comprise one or more of said tomaymicine derivatives covalently linked to a cell binding agent through a linking group that is present on the linker of the tomaymycin derivative. It also relates to the preparation of the tomaymicine derivatives and of the conjugate molecules.